Lancet:阜外医院:定量流量比指导的病变选择策略能明显改善PCI术后患者的临床结局

2021-11-05 MedSci原创 MedSci原创

在接受PCI的患者中,与标准血管造影指导相比,QFR指导的病变选择策略改善了1年的临床结果。

血管造影仍然是指导经皮冠状动脉介入(PCI)最广泛使用的方法。与视觉血管造影评估相比,基于压力线的生理测量能更准确地识别冠状动脉疾病患者的血流限制性病变。定量流量比(QFR)是一种新颖的基于血管造影术的方法,其无需使用压力线或腺苷就能快速计算分数血流储备。

既往的研究提示,QFR能改善PCI术后患者的临床结局。为此,在FAVOR III中国项目中,来自中国医学科学院阜外医院心内科、国家心血管病中心、国家心血管病临床研究中心和北京协和医院的心血管专家旨在通过使用QFR来估计分数血流储备,以确定是否可以通过选择病变进行PCI治疗来改善临床结果。结果发表在Lancet杂志上。

FAVOR III中国是一项在中国26家医院进行的多中心、盲法、随机、假对照的试验。年龄在18岁以上,患有稳定或不稳定心绞痛的患者,或在筛查前至少72小时发生过心肌梗死的患者,在冠状动脉中至少有一个直径为50-90%的狭窄病变,通过视觉评估,参考血管直径至少为2.5毫米的患者符合条件。

患者被随机分配到QFR指导的策略(仅在QFR≤0.80时进行PCI)或血管造影指导的策略(基于标准视觉血管造影评估的PCI)。主要终点是1年内主要不良心脏事件的发生率,即任何原因导致的死亡、心肌梗死或缺血导致的血管重建的综合。主要分析是在有意治疗人群中进行的。

在2018年12月25日至2020年1月19日期间,有3847名患者被纳入。在排除22名选择不接受PCI手术或被医生撤回的患者后,3825名参与者被纳入意向治疗人群(QFR引导组1913人,血管造影引导组1912人)。平均年龄为62.7岁(SD 10-1),2699人(70.6%)为男性,1126人(29.4%)为女性,1295人(33.9%)患有糖尿病,2428人(63-5%)出现了急性冠脉综合征

QFR指导组和常规PCI手术组患者一年期间MACE事件发生比

QFR指导组有110人(Kaplan-Meier估计率为5.8%)发生了1年的主要终点,而血管造影指导组有167人(8.8%)发生了1年的主要终点,QFR降低35%的主要终点风险(差异,-3%[95%CI-4.7至-1.4];危险比0.65[95%CI 0.51-0.83]),QFR指导组的心肌梗死和缺血导致的血管重建少于血管造影指导组的情况。

综上,在接受PCI的患者中,与标准血管造影指导相比,QFR指导的病变选择策略改善了1年的临床结果。

 

参考文献:

Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. https://doi.org/10.1016/S0140-6736(21)02248-0

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1831370, encodeId=3c7318313e0bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 20:03:23 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816179, encodeId=f15118161e9cf, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sat Jan 22 05:03:23 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633866, encodeId=5e0a163386613, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Feb 21 13:03:23 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843275, encodeId=0a9218432e566, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Wed Apr 20 11:03:23 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293774, encodeId=cca21293e7479, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486455, encodeId=34e5148645550, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-08-19 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1831370, encodeId=3c7318313e0bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 20:03:23 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816179, encodeId=f15118161e9cf, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sat Jan 22 05:03:23 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633866, encodeId=5e0a163386613, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Feb 21 13:03:23 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843275, encodeId=0a9218432e566, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Wed Apr 20 11:03:23 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293774, encodeId=cca21293e7479, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486455, encodeId=34e5148645550, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1831370, encodeId=3c7318313e0bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 20:03:23 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816179, encodeId=f15118161e9cf, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sat Jan 22 05:03:23 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633866, encodeId=5e0a163386613, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Feb 21 13:03:23 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843275, encodeId=0a9218432e566, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Wed Apr 20 11:03:23 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293774, encodeId=cca21293e7479, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486455, encodeId=34e5148645550, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-02-21 zxl736
  4. [GetPortalCommentsPageByObjectIdResponse(id=1831370, encodeId=3c7318313e0bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 20:03:23 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816179, encodeId=f15118161e9cf, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sat Jan 22 05:03:23 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633866, encodeId=5e0a163386613, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Feb 21 13:03:23 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843275, encodeId=0a9218432e566, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Wed Apr 20 11:03:23 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293774, encodeId=cca21293e7479, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486455, encodeId=34e5148645550, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1831370, encodeId=3c7318313e0bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 20:03:23 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816179, encodeId=f15118161e9cf, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sat Jan 22 05:03:23 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633866, encodeId=5e0a163386613, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Feb 21 13:03:23 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843275, encodeId=0a9218432e566, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Wed Apr 20 11:03:23 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293774, encodeId=cca21293e7479, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486455, encodeId=34e5148645550, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1831370, encodeId=3c7318313e0bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 20:03:23 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816179, encodeId=f15118161e9cf, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sat Jan 22 05:03:23 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633866, encodeId=5e0a163386613, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Feb 21 13:03:23 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843275, encodeId=0a9218432e566, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Wed Apr 20 11:03:23 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293774, encodeId=cca21293e7479, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486455, encodeId=34e5148645550, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Sun Nov 07 06:03:23 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

相关资讯

Eur Heart J:接受PCI的高出血风险患者替格瑞洛单药治疗效果分析

在完成3个月DAPT且未出现重大不良事件的接受PCI的HBR患者中,与替格瑞洛联合阿司匹林治疗相比,停用阿司匹林后进行替格瑞洛单药治疗可显著减少出血,而不会增加缺血事件。

NEJM:高出血风险患者PCI后双重抗血小板治疗

就净不良临床事件和主要不良心脏或大脑事件的发生情况而言,1个月的双重抗血小板治疗不劣于2个月以上的持续治疗;缩短治疗可使大出血或临床相关的非大出血发生率降低。

EHJ:孰优孰略?冠脉三支病变或左主干病变患者介入与开胸手术的比较

在3VD和/或LMCAD患者中,MAG可能是更理想的CABG配置,以实现比PCI更低的长期全因死亡率。

JAHA:经皮冠状动脉介入术后颅内出血的发生率、预测因素和对死亡率的影响

新发ICH最常发生在PCI后的早期,并且早期死亡的风险很高。对于ICH风险增加的患者,尤其是在PCI期间,需要谨慎使用抗血栓形成治疗。

NEJM:血流储备分数vs血管造影指导PCI对多支血管疾病ST段抬高型心肌梗死患者预后的影响

ST段抬高型心肌梗死准备接受完全性血管重建的患者,与传统的血管造影指导PCI相比,血流储备分数指导PCI在改善患者预后方面未表现出明显优势

Eur Heart J:糖尿病合并冠状动脉疾病患者经皮或手术血运重建术后10年全因死亡比较

无论是否伴有糖尿病,PCI与CABG对3VD和/或LMCAD患者10年全因死亡的治疗效果相似。然而,在接受胰岛素治疗的糖尿病患者中,CABG可能有生存获益。

拓展阅读

CIT 2018:QFR在患者水平诊断精度荟萃分析结果首发

3月24日上午,在CIT2018 PCR at CIT专场,丹麦奥胡思大学医院(Aarhus University Hospital)Niels Holm博士首次发布“定量血流分数的诊断精度-一项来自四个前瞻性多中心临床研究的患者水平荟萃分析”。这不仅意味着国际心血管领域对QFR临床价值的认可,也意味着QFR推向临床应用又迈出了坚实的一步。

重磅!阜外专家将携中国原创技术QFR新成果登上TCT舞台

10月29日~11月2日,全球介入心脏病学顶级学术会议TCT2017将在美国丹佛召开。大会最新研究的发布历来都是最受瞩目的重头戏,值得中国学者骄傲的是,10月31日,中国原创技术 QFR(定量血流分数)的临床验证研究FAVOR II China将在大会主会场作为First Report Investigation首次发布,由中国医学科学院阜外医院徐波教授带来精彩报告。